VERACYTE, INC.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYTNasdaqHealthcareDiagnostics & Research
$46.34 -1.65 (-3.44%)

Company Overview

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Price Chart

Historical Trend (Absolute Values)
VCYT Price
05/1305/2105/29

Financial Metrics

Market Capitalization$3.89B
P/E Ratio42.9074
Earnings Per Share (EPS)$1
Dividend Yield
Beta (Volatility)1.885
Price to Book (P/B)2.8081
52-Week Range$22.61 - $50.71

LAST SCRARED: May 30, 2026

Compare VCYT

Analyze valuation multiples and growth parameters side-by-side with other public equities.

Compare Stock Now
VersusHub

© 2026 VersusHub. All rights reserved.